Genetic Hair Loss: Treatments and Testing (2)Previous Page
For men, the HairDX test for Male Pattern Hair Loss reports on the presence or absence of a specific variation of the gene that governs androgenic alopecia. A positive test result indicates that there is a high risk of genetic hair loss. Men who test positive have approximately a 70% chance of going bald, while a negative result indicates that there is approximately a 70% chance of keeping the hair.
For women, the test offers a score (called the CAG score) which indicates the likelihood of hair loss. The lower test scores are associated with higher risks for significant hair loss, while the higher CAG scores indicate that there is a lower risk of losing the hair. Studies have shown that only 2.3% of women with a CAG score below 15 did NOT develop hair loss.
A second, related test, called the HairDX (RxR) test, has also been developed which measures an individual’s likely response to treatment with finasteride. Combined with the test for loss, the finasteride response test could help a man pinpoint a time at which he can begin the treatment for hair loss, and retain as much of his hair as possible, without having to undergo a re-growth period. Since, currently, the only FDA-approved treatments for hair loss are best at preserving the hair, being able to determine a likelihood of loss, and how effective the treatment will be for an individual are invaluable. Together, these tests can help an individual make a more informed decision and get better results from hair loss treatment.
A Bonus Benefit
The HairDX (RxR) test provides men with a CAG repeat score (like the one provided to women in the HairDX test). For men, the CAG repeat score is associated with an increased response to finasteride treatments. In addition, smaller CAG scores are associated with risk of developing a condition called Benign Prostatic Hyperplasia (or Enlarged Prostate).
Since an enlarged prostate can also lead to other problems – including urinary difficulties and sexual dysfunction – early warning is important. The takes on added importance when it is combined with the knowledge that another problem associated with enlarged prostate is the increased likelihood of undetected prostate tumors as a result of the enlarged prostate.
The company responsible for creating these tests is PharmaGenoma, Inc., a dermatology company founded in 2007 by leading researches and specialists in genetics and dermatology. The company is dedicated to the research and development of new prescription therapies for skin conditions tailored to the genetic make-up of an individual.
Currently, the test’s cost varies by the area in which you live but is less than $200 (U.S. Dollars). The test kit for male and female pattern baldness is listed with the U.S. FDA as a Class 1 medical device.
Stacy - Master Cosmetologist
Receding hair lines
A natural solution to hair loss